Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in other blood cancers and transplant
- Trial result
Other blood cancers and transplant
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden
Post-transplant cyclophosphamide (PTCy), followed by tacrolimus and mycophenolate, was used for graft-versus-host disease prophylaxis in the multicenter Phase 2 ACCESS trial (NCT04904588) of mismatched…
NCT04904588 - Trial result
Other blood cancers and transplant
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL
Vemurafenib is an oral BRAF inhibitor (active in BRAF V600E–mutant classic HCL) and rituximab is an anti-CD20 monoclonal antibody; in this prospective observational “Scripps regimen” study, patients received…
NCT05388123 - Trial result
Other blood cancers and transplant
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival
Tagraxofusp (tagraxofusp-erzs; ELZONRIS) is an IL-3Rα/CD123-targeted recombinant fusion “cytotoxin” (IL-3 linked to truncated diphtheria toxin) evaluated in a systematic review of adult BPDCN outcomes across…
NCT02113982 - New trial
Other blood cancers and transplant
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT.
Stanford University is running this non-randomized, open-label Phase 2 study to confirm feasibility and safety of an automated total marrow and lymphoid irradiation (TMLI) platform when embedded into a previously…
NCT07634536 Exploratory - New trial
Other blood cancers and transplant
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL
No disclosed MOA. We do not include details of trials without this basic information.
NCT07572006 First-in-human - New trial
Other blood cancers and transplant
Phase 2 cord blood transplantation (allogeneic hematopoietic stem-cell graft) after myeloablative conditioning in pediatric/AYA blood cancers
This Memorial Sloan Kettering Cancer Center, multi-cohort Phase 2 study tests whether umbilical cord blood transplantation (CBT)—used as a first allogeneic transplant in high-risk remission patients or as a second…
NCT07566377 Exploratory - New trial
Other blood cancers and transplant
Phase 2 TMLI conditioning + fludarabine/melphalan; IMRT marrow/lymphoid targeting + DNA-damaging chemo
City of Hope Medical Center is running this Phase 2 study testing whether total marrow and lymphoid irradiation (TMLI)—an intensity-modulated radiation approach that concentrates dose to marrow, lymph node chains,…
NCT07582172 Exploratory - New trial
Other blood cancers and transplant
Phase 1 thiotepa-based conditioning + de-escalated cyclophosphamide (DNA-alkylating immunosuppression) for alloSCT
This Phase 1, open-label transplant-conditioning study tests a thiotepa + busulfan + fludarabine (TBF) backbone before HLA-matched related or unrelated donor peripheral blood stem cell transplantation, paired with a…
NCT07565220 Exploratory - New trial
Other blood cancers and transplant
Phase 1 QUAIL-100 (LGNA-100) attenuated live bacterial γδ T-cell activator post-HSCT
This open-label, first-in-human, single ascending dose study tests QUAIL-100 (also described by Laguna Biotherapeutics as LGNA-100), an attenuated live bacterial immunotherapy intended to harness immune sensing…
NCT07573111 First-in-human - New trial
Other blood cancers and transplant
Pragmatic MRD-guided maintenance after allo-HCT; no single drug target
This prospective, open-label pragmatic study from the Medical College of Wisconsin tests whether using pre-transplant measurable residual disease (MRD) status to *assign* post–allogeneic hematopoietic cell transplant…
NCT07572929 Exploratory - New trial
Other blood cancers and transplant
Phase 2 treosulfan/fludarabine conditioning plus PTCy alkylator-based GVHD prophylaxis in allo-HSCT.
This Phase 2, single-center study at the Masonic Cancer Center (University of Minnesota) evaluates a reduced-intensity allogeneic hematopoietic stem cell transplant approach for hematologic diseases, including AML…
NCT07493538 Exploratory - New trial
Other blood cancers and transplant
Phase I trial of ICP-248, novel B-cell receptor modulator in mature B-cell malignancies
This study evaluates ICP-248’s safety, tolerability, pharmacokinetics, and preliminary efficacy alone or with CD20-directed antibodies in patients with relapsed/refractory CLL/SLL and mantle cell lymphoma. The trial…
NCT06351527 First-in-human - New trial
Other blood cancers and transplant
Phase II FLAG-Ida trial: fludarabine and cytarabine as DNA synthesis inhibitors with G-CSF boost
This trial evaluates immediate reduced‐intensity total body irradiation followed by donor hematopoietic cell transplant after FLAG-Ida chemotherapy in adults aged 60 and older with adverse-risk AML or high-grade…
NCT07046078 Exploratory - New trial
Other blood cancers and transplant
Phase 1 INCA035784 bispecific mAb targeting CALRmut and CD3 in MPN
This Phase 1 open-label study of INCA035784—a bispecific antibody targeting CALR-mutant and CD3—is evaluating safety, tolerability, and optimal dosing in patients with myeloproliferative neoplasms, including…
NCT07008118 First-in-human - New trial
Other blood cancers and transplant
Phase 2 WU-CART-007: CD7-targeted CAR-T Cell Therapy for R/R T-ALL and T-LBL
This trial evaluates the efficacy of a single intravenous infusion of WU-CART-007—an anti-CD7 CAR-T cell therapy administered after lymphodepletion—in relapsed or refractory T-cell acute lymphoblastic leukemia and…
NCT06514794 Registrational - New trial Spotlight
Other blood cancers and transplant
Phase 1 trial of ruxolitinib, a JAK1 inhibitor for preventing GVHD
Investigating biomarker-guided ruxolitinib for preventing chronic GVHD in post-transplant patients, this Phase 1 trial compares ruxolitinib monotherapy starting about 105 days after allogeneic HCT versus…
NCT07025538 Exploratory - New trial
Other blood cancers and transplant
Phase 1 HaploCord Transplant: Unmodified cord blood graft for hematologic malignancies.
This trial at Case Comprehensive Cancer Center in Cleveland investigates whether combining haplo‐identical donor and cord blood transplants can yield durable disease‐free survival in patients with AML or ALL.…
NCT06904482 Exploratory - New trial
Other blood cancers and transplant
Phase 1 study: Tetrahydrouridine-Decitabine, DNA methyltransferase and cytidine deaminase inhibitor combo.
This Phase 1 trial from EpiDestiny, Inc. evaluates weekly oral administrations of tetrahydrouridine followed by decitabine over 24 weeks in patients with relapsed or refractory myelodysplastic syndromes. The study…
NCT07006025 Exploratory - Trial result Spotlight
Other blood cancers and transplant
Revumenib + AZA/VEN Hits 88% ORR and Universal MRD-Negativity in Older NPM1m/KMT2Ar AML
Revumenib, an oral menin inhibitor that disrupts the menin-KMT2A/NPM1 transcriptional axis, was added to frontline azacitidine + venetoclax in a phase I dose-escalation/expansion study (NCT03013998) enrolling 43…
NCT03013998 - Trial result
Other blood cancers and transplant
IDH Triplet (AZA/DEC + Venetoclax + Ivo/Enas) Delivers 92% CRc and 69% 2-Year OS in Intensive chemo-Ineligible AML
A single-center series (NCT03471260/NCT04774393) treated 60 newly diagnosed, intensive-chemo–ineligible IDH-mutated AML patients with a hypomethylating agent (HMA) azacitidine or oral decitabine plus venetoclax and…
NCT03471260 - New trial
Other blood cancers and transplant
Phase 1b CMV-MVA Triplex Vaccine, MVA-based CMV immunotherapy
This trial by City of Hope evaluates the safety and potential efficacy of the vaccine alone or with antiviral agents in haploidentical stem cell transplant donors and recipients at risk for CMV viremia. Eligible…
NCT07020533 Exploratory - New trial
Other blood cancers and transplant
Phase I/II AZD9829: CD123-directed mAb Topo1 inhibitor ADC
This open-label, multicenter study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD9829 administered intravenously as monotherapy or in combination. It enrolls patients…
NCT06179511 First-in-human - Trial result
Other blood cancers and transplant
Asciminib (STAMP/BCR-ABL1) pediatric formulation hits 64-67% MMR with adult-equivalent PK in Ph+ CML-CP
Asciminib, an allosteric BCR-ABL1 STAMP inhibitor, was evaluated in the Phase Ib/II ASC4Kids study (NCT04925479). Nineteen children (1–<18 y) with Philadelphia chromosome-positive Chronic Myeloid Leukemia in the…
NCT04925479 - Trial result
Other blood cancers and transplant
ASC2ESCALATE: Asciminib STAMP inhibitor clears BCR-ABL1 ≤ 1% in 83% after one prior TKI
Asciminib, an allosteric BCR-ABL1 “STAMP” inhibitor, was tested in the single-arm Phase 2 ASC2ESCALATE trial (NCT05384587) in 101 adults with chronic-phase CML who had failed or were intolerant to exactly one TKI.…
NCT05384587 - Trial result
Other blood cancers and transplant
CD7-directed allogeneic CAR-T WU-CART-007 delivers 73% complete remissions in relapsed/refractory T-ALL/LBL
WU-CART-007 is a fratricide-resistant, healthy-donor CAR-T that targets CD7. In the phase 1/2 dose-escalation/expansion trial (NCT04984356), 28 heavily pre-treated patients received a single infusion after standard…
NCT04984356 - New trial
Other blood cancers and transplant
Phase I/II trial of AZD5492, trispecific T cell-engaging antibody targeting CD20.
This open-label study employs dose escalation and expansion to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492 monotherapy in patients with relapsed or refractory CD20+ B-cell…
NCT06542250 - New trial
Other blood cancers and transplant
Phase 1 trial of LYT-200, a galectin-9 directed mAb.
This open-label, multi-center study evaluates LYT-200 administered via IV infusion as monotherapy or combined with venetoclax and hypomethylating agents in patients with relapsed/refractory AML or high-risk MDS in a…
NCT05829226 - New trial
Other blood cancers and transplant
Phase 2 ASTX727 Trial: Cytidine Deaminase Inhibition in Accelerated/Blast-Phase MPNs
This Phase 2 trial by the National Cancer Institute compares ASTX727 alone versus ASTX727 plus iadademstat, an LSD1 inhibitor, in patients with accelerated or blast-phase Philadelphia chromosome-negative…
NCT06661915 - New trial
Other blood cancers and transplant
Phase 1/2 Trial of ARD103 CLL-1 CAR-T in R/R AML/MDS
ARCE Therapeutics is conducting an open-label, multicenter trial to assess ARD103—a CLL-1 directed CAR-T—administered alongside cyclophosphamide and fludarabine in relapsed/refractory AML or MDS patients.
NCT06680752 - New trial
Other blood cancers and transplant
Phase 2 Trial of Pacritinib for R/R Waldenström Macroglobulinemia (JAK2/FLT3 Inhibitor)
This Phase 2 study evaluates pacritinib—a JAK2 and FLT3 inhibitor—for relapsed/refractory Waldenström macroglobulinemia patients (including those ineligible for BTK inhibitors) with a treatment plan that includes…
NCT06986174
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.